The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.